RPRyan F. Paterson

Ryan F. Paterson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ryan F. Paterson has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Ureteral Stents: A Necessary Evil?

    by Ali Al-Gonaim, Connor M. Forbes, Ryan F. Paterson, K. F. Victor Wong, Dirk Lange, Ben H. Chew

  • Tri-layer ureteral stents, with anti-encrustation surface, offer improved comfort: results from an international stent registry

    by Runhan Ren, K.F. Victor Wong, Connor M. Forbes, Yuanyuan Ji, Alexander P. Glaser, Ryan F. Paterson, Kazumi Taguchi, Ojas Shah, Edouard Tariel, Channa Amarasekera, et al.

    A tri-layer ureteral stent with novel coating lining the inner and outer surfaces (Tria™) was designed to reduce encrustation. We assessed technical success, complications, and patient symptoms in an international prospective stent registry conducted from 2020 to 2023. Outcomes included technical success, infections, and encrustation rates. Patient-reported PROMIS Pain Intensity (3a) and Pain Interference (6b) scores were obtained at time of index procedure, stent removal, and post-stent removal. Tria stents were compared to non-Tria stents grouped together. Of 359 total patients, 271 had a unilateral stent placed for stone management procedures. Tria vs. non-Tria groups were comparable in age (55.9y vs. 58.7y), gender (57.8% vs. 56.4% male), BMI (28.9 vs. 29.7 kg/m2), and stent indwell times (11.8 vs. 9.9 days). Pain interference scores (p = 0.025) were lower in patients with Tria stents, and pain intensity scores approached significance (p = 0.052). Non-Tria patients reported significantly larger decreases from the week prior to stent removal to post-stent removal in both domains (p = 0.0245, p = 0.0216). Infection (Tria 1.9% vs. non-Tria 3.4%, p = 0.45) and encrustation rates (Tria 1.3% vs. non-Tria 0%, p = 0.36) were both low and non-significantly different. Patients with Tria stents were more comfortable than non-Tria stents in the week prior to stent removal and post-stent removal visits.


  • Open Access

    Burst wave lithotripsy - a paradigm shift: inferences from a scoping review

    by Steffi Kar Kei Yuen, Vineet Gauhar, Chu Ann Chai, Connor M. Forbes, Victor K. F. Wong, Ryan F. Paterson, Ivan Ching Ho Ko, Joseph Li, Daniele Castellani, Ben H. Chew

    Purpose: Urolithiasis, a condition affecting approximately 10% of the global population, is primarily treated with Shock Wave Lithotripsy (SWL) and endoscopic methods. However, SWL’s high-pressure pulses can cause tissue injury, often necessitates some level of anaesthesia, and may require repeated sessions or ancillary treatment to achieve stone free status. Burst Wave Lithotripsy (BWL) emerges as a promising alternative, utilizing multi-cycle, ultrasound bursts at lower pressure amplitude to fragment stones, while minimizing cavitation under real-time imaging in a portable manner. Methods: This scoping review evaluated BWL’s efficacy, safety, and clinical potential. A systematic search identified 19 eligible studies, including in vitro experiments, preclinical trials, and human clinical trials. Results: In vitro studies demonstrated BWL’s capability to fragment urinary stones of diverse compositions with high comminution rates. Higher ultrasound frequencies produced smaller fragments (< 1 mm), while lower frequencies resulted in larger fragments (3–4 mm), allowing for controlled fragmentation tailored to clinical needs. Preclinical trials in porcine models showed lower pressure and reduced cavitation, which account for BWL’s safety, causing less associated tissue injury even in anticoagulated subjects. Human trials reported BWL as well tolerated in awake patients with high fragmentation success rates (88–91%) and low complication rates. BWL offers distinct advantages, including lower cavitation and tissue injury risks, portability, and anaesthesia-free application. Ongoing trials aim to validate BWL’s efficacy and explore its combined use with ultrasonic propulsion. Conclusion: BWL represents a paradigm shift in lithotripsy, offering controlled fragmentation, reduced tissue injury, fragment propulsion and portability for office-based or ambulatory care. Early clinical evidence underscores its safety and efficacy, even in anticoagulated patients. While large-scale trials are needed to solidify its role, BWL’s procedural flexibility positions it as a transformative alternative to SWL, poised to redefine urolithiasis management.


  • Open Access

    Break Wave Lithotripsy for Urolithiasis: Results of the First-in-Human International Multi-Institutional Clinical Trial

    by Ben H. Chew, Jonathan D. Harper, Roger L. Sur, Thomas Chi, Shubha De, Anne R. Buckley, Ryan F. Paterson, Victor K. F. Wong, Connor M. Forbes, M. Kennedy Hall, et al.

    This study reports on a prospective, multicenter, single-arm, clinical trial utilizing the SonoMotion (San Mateo, California) Break Wave lithotripsy (BWL) device to fragment urinary stones. Patients with a urinary stone underwent a single treatment of 30 minutes and peak negative pressure of 4.5 to 8 MPa. Subjects were contacted and outcomes assessed at 7, 14, and 35 days after treatment, with clinical follow-up and CT imaging 70 ± 14 days postprocedure. The primary objectives were to assess the safety (hematomas, complications, etc) and effectiveness of BWL (any fragmentation, residual fragments ≤4 mm or ≤2 mm, and completely stone-free rate) as assessed via noncontrast CT-kidneys, ureters, and bladder. Forty-four patients with a ureteral (43%) or renal (57%) stone were treated across 5 centers. Stone fragmentation occurred in 88% of cases; 70% had fragments ≤ 4 and 51% ≤ 2 mm, while 49% were completely stone free on CT; no serious adverse events were reported. Eighty-six percent of patients received either no analgesic medication at all (50%) or minor analgesia (36%). After determining optimal therapy settings, 36 patients were treated and the effectiveness improved exhibiting fragmentation in 92% (33/36), residual fragments ≤ 4 mm in 75% and 58% with fragments ≤ 2 mm with 58% completely stone free. Effectiveness was less in subjects with lower pole stones with 81% fragmentation, 71% having fragments ≤ 4 mm, 29% with fragments ≤ 2 mm, and 29% completely stone free; of distal ureteral stone patients, 89% were completely stone free. BWL offered safe and effective noninvasive stone therapy requiring little to no anesthesia and was carried out successfully in nonoperative environments. ClinicalTrials.gov identifier: NCT03811171.


  • Open Access

    Safety and Efficacy of Simultaneous Bilateral Percutaneous Nephrolithotomy

    by Victor K. F. Wong, Colin J. Lundeen, Ryan F. Paterson, Kymora B. Scotland, Ben H. Chew

    A retrospective review was conducted to evaluate intraoperative and patient outcomes following simultaneous bilateral percutaneous nephrolithotomy (SB-PCNL). Target stone characteristics, operative time, hospitalization length, post-operative complications, blood loss, opioid use, pain, and stone-free rates were evaluated. In total, 42 patients with large renal stones (>20 mm2) were identified for this study, and 38% of them achieved stone-free status with no residual fragments apparent on post-operative day one CT imaging. The maximum mean residual fragment size was 3.67 mm2 and average number of residual fragments following the procedures was 1.63. The rates of blood loss, post-operative complications, opioid use, and pain from the study cohort were similar to the reported outcomes of studies conducted by others. The potential benefits of a single procedure and anesthesia to treat bilateral stone burdens, lower total pain medication prescribed, and lower hospital costs render SB-PCNL as an attractive option in the treatment of bilateral kidney stones.


  • Ureteral Stents

    by Ben H. Chew, Ryan F. Paterson, Dirk Lange

  • MULTI-CENTER ANALYSIS OF POST-OPERATIVE CT-DETECTED COMPLICATIONS FOLLOWING PERCUTANEOUS NEPHROLITHOTOMY

    by Michelle J Semins, Leonid Bartik, Mitchell R Humphreys, Ojas D Shah, Nicole L Miller, Ben H Chew, Ryan F Paterson, Brian R Matlaga


  • A MULTICENTER COMPARISON OF THE SAFETY AND EFFECTIVENESS OF URETEROSCOPIC LASER LITHOTRIPSY IN OBESE AND NORMAL WEIGHT PATIENTS

    by Ben H Chew, Dirk Lange, Olga Arsovska, Rochelle Leung, Ryan F. Paterson, Joel M H Teichman, Rafael N Nunez, Aron Bruhn, Hernan O. Altomar, Mitchell R. Humphreys, et al.